WO1987004070A1 - Aqueous dispersions of waxes and lipids for pharmaceutical coating - Google Patents

Aqueous dispersions of waxes and lipids for pharmaceutical coating Download PDF

Info

Publication number
WO1987004070A1
WO1987004070A1 PCT/US1987/000034 US8700034W WO8704070A1 WO 1987004070 A1 WO1987004070 A1 WO 1987004070A1 US 8700034 W US8700034 W US 8700034W WO 8704070 A1 WO8704070 A1 WO 8704070A1
Authority
WO
WIPO (PCT)
Prior art keywords
wax
coating
lipid
coating powder
process according
Prior art date
Application number
PCT/US1987/000034
Other languages
French (fr)
Inventor
Suresh C. Bagaria
Nicholas G. Lordi
Original Assignee
Research Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corporation filed Critical Research Corporation
Publication of WO1987004070A1 publication Critical patent/WO1987004070A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/10—Coating with edible coatings, e.g. with oils or fats
    • A23P20/11—Coating with compositions containing a majority of oils, fats, mono/diglycerides, fatty acids, mineral oils, waxes or paraffins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Definitions

  • This invention relates to aqueous dispersions of waxes and lipids for pharmaceutical coating and more particularly is concerned with the preparation of an aqueous system for the coating of pharmaceutical solids, i.e. medicaments and the like, with waxes or lipids alone or in combination.
  • the techniques employed for the application of wax and lipid coatings on solid dosage forms include the hot-melt e application whereby the waxes and lipids are melted with an oil-soluble emulsifying agent and are applied to tablets or granules rotating in a coating pan.
  • Another method in use employs organic solvent solutions of waxy materials in which the waxes and lipids Q are dissolved in a suitable organic solvent such as chloroform and the organic solution is then applied on tablets or pellets in a conventional coating pan, for example.
  • a suitable organic solvent such as chloroform
  • Spray, congealing is also in use and presents the 5 advantage of producing directly a free flowing powder by spraying a suspension of finely-divided powdered medicament, molten wax and lipid into solid particulate form.
  • Aqueous film coating has gained use recently.
  • a typical process involves dispersing a finely-divided powder 0 of hydroxypropylmethylcellulose phthalate in an aqueous medium containing triacetin to give an aqueous coating liquid, spraying the coating onto the surface of a solid dosage form and thereafter drying the thus coated solid dosage form to provide an enteric coating. 5 ⁇ None of these processes have been completely satisfactory.
  • Organic coating liquids are undesirable as the use of large amounts of organic solvents involves problems of explosion or fire hazard as well as possible toxic effects 5 and environmental pollution.
  • the hot-melt and spray congealing methods involve the use of special equipment which is costly.
  • the present invention involves a novel formulation and process for converting waxes and lipids used for 5 pharmaceutical and food coating encapsulation into a solid powder which can be reconstituted with water into an aqueous coating system for application as a protective, enteric and/or controlled release coating of drug-containing granules, pellets and tablets.
  • the aqueous dispersion method is a novel formulation and process for converting waxes and lipids used for 5 pharmaceutical and food coating encapsulation into a solid powder which can be reconstituted with water into an aqueous coating system for application as a protective, enteric and/or controlled release coating of drug-containing granules, pellets and tablets.
  • J_ Q of the present invention can be used to coat heat-sensitive materials as the product is not exposed to excessively high temperatures.
  • the present emulsion or dispersion system can be prepared with low viscosities at high solids content; such coating systems containing 20-30% solids can readily be— j_c j applied using conventional fluidized bed or pan-coating technology.
  • the novel aqueous film coating system of the present invention the coating thickness and uniformity of coating of drugs can be more effectively controlled and the 0 solid readily dispersible powdered form eliminates problems associated with shipping and shelf-stability of aqueous dispersions.
  • the present coating system may contain a wide range of wax and lipid materials alone or in combination. Pigments, plasticizers, both water and water-insoluble
  • polymers as well as drugs may easily be incorporated into the present coating system.
  • the present invention involves the emulsification of a lipid/wax mixture followed by spray drying to form a powder.
  • the resultant powder is readily dispersible in water and may be coated on drug-containing granules, pellets, tablets and the like.
  • the aqueous dispersions of waxes !_ and lipids may be used for pharma'ceutical coating applications of medicaments as, for instance, protective coatings, enteric coatings, sustained-release coatings and the like.
  • a typical formulation may include a lipid, i.e. partially hydrogenated cottonseed oil, an emulsifying agent, i.e., polysorbate, and/or a wax, i.e. castor wax.
  • the partially hydrogenated cottonseed oil may be heated in a water bath at 80-85°C.
  • a o solution of polysorbate (Tween 65) heated to 90°C. is then added to the molten lipid mass with constant stirring.
  • a dispersion of Veegum K in water heated to 90°C. is then added with stirring.
  • An antifoam agent for example, Antifoam AF, is added and made
  • ] _c up to weight by adding hot distilled water.
  • the emulsion is shock-cooled in an ice-bath with constant stirring.
  • a smooth emulsion having a particle size between 1-5 microns is obtained.
  • the emulsion may then be applied to the coating of
  • 2o pellets for example, by spray coating drug-coated non-pareil seeds in the coating vessel of a fluid-bed coating unit such as the Uni-Glatt in the usual manner.
  • the spraying is carried out continuously . until the desired increase in mean weight of drug-beads is achieved.
  • the wax component is employed in an amount of from about 10% to about 30%, and preferably from about 15% to about 20%, by weight, of the total quantity of the emulsion.
  • the lipid component when employed, is employed in an amount of from about 10% to about 30%, and preferably from about 15% to about 20%, by weight, of the total quantity of the emulsion.
  • the emulsifying agent is employed in an amount from about 0.5% to about 5%, and preferably from about 1% to about 3%, by weight, of the total quantity of the emulsion.
  • Water is employed in an amount sufficient to balance the formulation.
  • the wax component of the emulsion may comprise any ⁇ _0 paraffin wax obtained from petroleum oil and may include microcrystalline wax such as obtained from petroleum residues; also, paraffin waxes modified with various polymers, e.g. polyethylene, or copolymers such as ethylene-vinyl acetate copolymers and similar polymeri ⁇ - 2_ materials may be included.
  • paraffin v/ax having a melting point of from about 115°F. to about 150°F. is preferred, and such wax may comprise high molecular weight hydrocarbons, comprising, generally, straight-chain compounds having a crystalline structure in solid form. 2o Microcrystalline wax may be employed, as hereinbefore indicated, and is obtained from petroleum oil.
  • This material may possess a melting point of about 150°F. to about 190°F. and contains a substantial portion of high molecular weight hydrocarbons having branched-chain and ring structures.
  • This 2 material is more plastic in nature than paraffin wax.
  • Petrolatum is commercially obtained from petroleum and comprises a mixture of microcrystalline wax and petroleum oil.
  • Particularly useful waxes and lipids for use in the 0 present invention include:
  • Surface active agents for use in the present invention may be of the anionic or nonionic type.
  • the emulsifier employed in the wax/lipid emulsions of the present invention may be of the nonionic type and may also include
  • emulsifiers of the anionic type in combination therewith.
  • Many nonionic emulsifiers can be used in this emulsion provided the critical relationship between oil solubility and water solubility is maintained.
  • Typical of such emulsifiers are mixtures of sorbitan monooleate and poly ⁇ xyethylene
  • Typical other nonionic emulsifiers suitable for use in these wax/lipid emulsions are polyoxyethylene ethers of octyl or nonylphenol having variable amounts of ethylene oxide content per mole of finished product required to provide the oil and water 5 solubility characteristics.
  • polyoxyethylene ethers of octyl phenol having about 5 moles of ethylene oxide per mole of finished product when blended with a like amount of polyoxyethylene ethers of octyl phenol having about 10 moles of ethylene oxide per mole of finished 0 product provides an emulsifier combination having the desired water and oil solubility.
  • ethylene oxide content is reduced, oil solubility is enhanced, whereas as the ethylene oxide content is increased, water solubility 5 ] _ is enhanced.
  • a blended product having sufficient oil-soluble and water-soluble constituents and possessing an average ethylene oxide content per mole of finished product between about 5 and 10 is quite satisfactory.
  • Other nonionic emulsifiers contemplated within the scope of the present emulsions are exemplified by partial esters of fatty acids (e.g. palmitic, stearic, oleic and the like) and hexitol anhydrides (hexitans and hexides) derived from sorbitol.
  • Suitable deflocculating agents such as sodium hexametaphosphate, sodium tetraphosphate, sodium tripolyphosphate and potassium metaphosphate may advantageously be used in the present composition in amounts from about 0% to about 1% by weight.
  • Antifoam AF (Semithicon Emulsion) 10 Distilled Water q.s. 1000
  • the coating emulsion of the composition described in Example 1 is spray dried in a laboratory size spray dryer. j
  • the drying conditions selected are such that the spray drying chamber temperature is maintained at least 5°C. below the melting point of the wax.
  • a free-flowing powder is obtained with an average particle size of 1-5 micron.
  • 200 g of the above-described spray dried powder is dispersed in sufficient distilled water to give 500 g of final dispersion.
  • a suitable lab mixer such as a Brookfield mixer or Waring blender is used to ensure complete dispersion j_ of the spray dried powder in the aqueous media.
  • 500 g of drug granulation are placed in the coating vessel of a Uni-Glatt coater.
  • the above-described coating Q dispersion is sprayed continuously until the desired amount of lipid coat is applied.
  • the spray dried lipid emulsion, talc and _30 citroflex-4 are dispersed in distilled water with the help of a suitable lab mixer.
  • the resulting dispersion is passed through a homogenizer to ensure completeness of dispersion.
  • Drug-beads are coated in a fluid bed coating unit as described in Example 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Coating of pharmaceutically useful solids with an emulsion comprising a wax/lipid, an emulsifying agent and water, which emulsion can be spray dried to form a powder which can subsequently be dispersed in water and coated onto the surface of medicaments to form a protective, enteric and/or controlled release of drug-containing granules, pellets and tablets.

Description

AQUEOUS DISPERSIONS OF WAXES AND LIPIDS FOR PHARMACEUTICAL COATING
This invention relates to aqueous dispersions of waxes and lipids for pharmaceutical coating and more particularly is concerned with the preparation of an aqueous system for the coating of pharmaceutical solids, i.e. medicaments and the like, with waxes or lipids alone or in combination. 0
The techniques employed for the application of wax and lipid coatings on solid dosage forms include the hot-melt e application whereby the waxes and lipids are melted with an oil-soluble emulsifying agent and are applied to tablets or granules rotating in a coating pan.
Another method in use employs organic solvent solutions of waxy materials in which the waxes and lipids Q are dissolved in a suitable organic solvent such as chloroform and the organic solution is then applied on tablets or pellets in a conventional coating pan, for example.
Spray, congealing is also in use and presents the 5 advantage of producing directly a free flowing powder by spraying a suspension of finely-divided powdered medicament, molten wax and lipid into solid particulate form.
Aqueous film coating has gained use recently. A typical process involves dispersing a finely-divided powder 0 of hydroxypropylmethylcellulose phthalate in an aqueous medium containing triacetin to give an aqueous coating liquid, spraying the coating onto the surface of a solid dosage form and thereafter drying the thus coated solid dosage form to provide an enteric coating. 5 η None of these processes have been completely satisfactory. Organic coating liquids are undesirable as the use of large amounts of organic solvents involves problems of explosion or fire hazard as well as possible toxic effects 5 and environmental pollution. The hot-melt and spray congealing methods involve the use of special equipment which is costly.
The use of aqueous polymer solutions for film coating purposes is limited to relatively low solids contents
•J_Q since the viscosity of such solutions rises sharply with an increase in concentration or molecular weight of the polymer. As a consequence of this relatively low polymer con¬ centration, a number of separate layers of polymer must be built up in order to obtain a coating, of adequate thickness
]r for surface protection. This, in addition to the slow rate of evaporation of water and relatively large amounts of water to be removed, may result in a very long processing time. Furthermore, water sensitive drugs are prone to hydrolysis due to the long exposure of the drugs to water and many tablets
2 must be sealed with water barriers such as shellac coatings prior to aqueous film coating.
25
30
5 The present invention involves a novel formulation and process for converting waxes and lipids used for 5 pharmaceutical and food coating encapsulation into a solid powder which can be reconstituted with water into an aqueous coating system for application as a protective, enteric and/or controlled release coating of drug-containing granules, pellets and tablets. The aqueous dispersion method
J_Q of the present invention can be used to coat heat-sensitive materials as the product is not exposed to excessively high temperatures. The present emulsion or dispersion system can be prepared with low viscosities at high solids content; such coating systems containing 20-30% solids can readily be— j_cj applied using conventional fluidized bed or pan-coating technology.
Kith the novel aqueous film coating system of the present invention the coating thickness and uniformity of coating of drugs can be more effectively controlled and the 0 solid readily dispersible powdered form eliminates problems associated with shipping and shelf-stability of aqueous dispersions. The present coating system may contain a wide range of wax and lipid materials alone or in combination. Pigments, plasticizers, both water and water-insoluble
25 polymers as well as drugs, may easily be incorporated into the present coating system.
20 The present invention involves the emulsification of a lipid/wax mixture followed by spray drying to form a powder. The resultant powder is readily dispersible in water and may be coated on drug-containing granules, pellets, tablets and the like. The aqueous dispersions of waxes !_ and lipids may be used for pharma'ceutical coating applications of medicaments as, for instance, protective coatings, enteric coatings, sustained-release coatings and the like. 5 A typical formulation may include a lipid, i.e. partially hydrogenated cottonseed oil, an emulsifying agent, i.e., polysorbate, and/or a wax, i.e. castor wax. In carrying out the present invention the partially hydrogenated cottonseed oil may be heated in a water bath at 80-85°C. A o solution of polysorbate (Tween 65) heated to 90°C. is then added to the molten lipid mass with constant stirring. A dispersion of Veegum K in water heated to 90°C. is then added with stirring. The crude emulsion is then homogenized. An antifoam agent, for example, Antifoam AF, is added and made
]_c up to weight by adding hot distilled water. The emulsion is shock-cooled in an ice-bath with constant stirring. A smooth emulsion having a particle size between 1-5 microns is obtained.
The emulsion may then be applied to the coating of
2o pellets, for example, by spray coating drug-coated non-pareil seeds in the coating vessel of a fluid-bed coating unit such as the Uni-Glatt in the usual manner. The spraying is carried out continuously.until the desired increase in mean weight of drug-beads is achieved. The beads thus obtained
25 have a smooth lustrous surface. If desired, suitable drug granulations-may be coated with the described coating dispersion by spraying until the desired amount of lipid coat is applied.
With respect to the individual components 30 of tne lipid/wax composition of the present invention, the wax component is employed in an amount of from about 10% to about 30%, and preferably from about 15% to about 20%, by weight, of the total quantity of the emulsion.
5 τ_ The lipid component, when employed, is employed in an amount of from about 10% to about 30%, and preferably from about 15% to about 20%, by weight, of the total quantity of the emulsion. The emulsifying agent is employed in an amount from about 0.5% to about 5%, and preferably from about 1% to about 3%, by weight, of the total quantity of the emulsion. Water is employed in an amount sufficient to balance the formulation.
The wax component of the emulsion may comprise any τ_0 paraffin wax obtained from petroleum oil and may include microcrystalline wax such as obtained from petroleum residues; also, paraffin waxes modified with various polymers, e.g. polyethylene, or copolymers such as ethylene-vinyl acetate copolymers and similar polymeriσ- 2_ materials may be included. In general, paraffin v/ax having a melting point of from about 115°F. to about 150°F. is preferred, and such wax may comprise high molecular weight hydrocarbons, comprising, generally, straight-chain compounds having a crystalline structure in solid form. 2o Microcrystalline wax may be employed, as hereinbefore indicated, and is obtained from petroleum oil. This material may possess a melting point of about 150°F. to about 190°F. and contains a substantial portion of high molecular weight hydrocarbons having branched-chain and ring structures. This 2 material is more plastic in nature than paraffin wax. Petrolatum is commercially obtained from petroleum and comprises a mixture of microcrystalline wax and petroleum oil.
Particularly useful waxes and lipids for use in the 0 present invention include:
Carnauba Wax - melting point 79-85°C. Ceresin Wax - melting point 72-75°C. Microcrystalline Wax - melting point 70-80°C. Glyceryl Monostearate - melting point 60-65°C.
Partially Hydrogenated Cottonseed Oil - melting point 62-65°C.
Hydrogenated Castor Oil - melting point 85-87°C. (Cutina HR/Castσr Wax)
In addition to the foregoing waxes/lipids, the following have been successfully emulsified and spray dried. Hoechst Wax E, partially hydrogenated palm oil, Bees wax, Carnuba Wax and Bees Wax mixture, Cutina HR and Glyceryl Monostearate Mixture, Hoechst wax, Bees wax and Paraffin wax iσ mixture.
Surface active agents for use in the present invention may be of the anionic or nonionic type. The emulsifier employed in the wax/lipid emulsions of the present invention may be of the nonionic type and may also include
15 emulsifiers of the anionic type in combination therewith. Many nonionic emulsifiers can be used in this emulsion provided the critical relationship between oil solubility and water solubility is maintained. Typical of such emulsifiers are mixtures of sorbitan monooleate and polyσxyethylene
20 sorbitan monooleate. Typical other nonionic emulsifiers suitable for use in these wax/lipid emulsions are polyoxyethylene ethers of octyl or nonylphenol having variable amounts of ethylene oxide content per mole of finished product required to provide the oil and water 5 solubility characteristics. Thus, for example, a portion of polyoxyethylene ethers of octyl phenol having about 5 moles of ethylene oxide per mole of finished product when blended with a like amount of polyoxyethylene ethers of octyl phenol having about 10 moles of ethylene oxide per mole of finished 0 product, provides an emulsifier combination having the desired water and oil solubility. As the ethylene oxide content is reduced, oil solubility is enhanced, whereas as the ethylene oxide content is increased, water solubility 5 ]_ is enhanced. A blended product having sufficient oil-soluble and water-soluble constituents and possessing an average ethylene oxide content per mole of finished product between about 5 and 10 is quite satisfactory. Other nonionic emulsifiers contemplated within the scope of the present emulsions are exemplified by partial esters of fatty acids (e.g. palmitic, stearic, oleic and the like) and hexitol anhydrides (hexitans and hexides) derived from sorbitol. These materials, to which polyoxyethylene chains have been j_Q added to the nonesterified hydroxyls to increase water solubility, are blended with the untreated material to provide solubility balance. Also usable in this area are the condensation products of ethylene oxide and relatively high molecular weight polypropylene glycol. The molecular weight j_ of the polypropylene glycol portion may be 1,000-2,000. The molecular weight of the compound may be as high as 8,000. As emulsion stabilizing agents (co-emulsifiers) there may be mentioned the alcohols cetyl alcohol, stearyl alcohol, lauryl alcohol and the like. Acids such as stearic
20 acid, lauric acid, palmitic acid, etc. may also be used as well as the hydrocolloids methyl cellulose and sodium carboxymethylcellulose. Such co-emulsifiers may be employed in amounts from 0% to 2% by weight. Suitable deflocculating agents such as sodium hexametaphosphate, sodium tetraphosphate, sodium tripolyphosphate and potassium metaphosphate may advantageously be used in the present composition in amounts from about 0% to about 1% by weight. The invention will be described in greater detail in conjunction with the following specific examples in which
_ 0 the parts are by weight unless otherwise specified.
35 EXAMPLE 1
PREPARATION OF EMULSION:
Ingredients Grams
5 Partially Hydrogenated Cottonseed Oil 250
Polysorbate 65 (Tween 65) 15
Veegum K 10
Antifoam AF (Semithicon Emulsion) 10 Distilled Water q.s. 1000
10
250 g of partially hydrogenated cottonseed oil is heated in a water bath at 80-85°C. A 10% solution of Tween
65, heated to 90°C, is then added to the molten lipid mass with constant stirring using a suitable lab mixer such as a
2 Brookfield counter rotating mixer. A 4% dispersion of Veegum K in water heated to 90°C. is then added with stirring. The crude emulsion is then homogenized using a homomixer or other suitable homogenizer. The Antifoam AF is added and made up to weight by adding hot distilled water. The emulsion is
20. shock-cooled in an ice-bath with constant stirring. A smooth emulsion having a particle size between 1-5 micron is obtained.
COATING OF PELLETS:
2 600 g of drug-coated non-pareil seeds are placed in the coating vessel of a fluid-bed coating unit such as the Uni-Glatt. The drug beads are sprayed with the coating emulsion of the above-described composition according to the usual method. The bed temperature is closely monitored and
3Q is kept 3-5°C. lower than melting point of the lipid. The spraying is carried out continuously until the desired increase in mean weight of drug-beads is achieved. The beads thus obtained have a smooth and lustrous surface.
35 EXAMPLE 2
SPRAYING DRYING OF EMULSION:
The coating emulsion of the composition described in Example 1 is spray dried in a laboratory size spray dryer. j The drying conditions selected are such that the spray drying chamber temperature is maintained at least 5°C. below the melting point of the wax. A free-flowing powder is obtained with an average particle size of 1-5 micron.
ID PREPARATION OF COATING DISPERSION:
200 g of the above-described spray dried powder is dispersed in sufficient distilled water to give 500 g of final dispersion. A suitable lab mixer such as a Brookfield mixer or Waring blender is used to ensure complete dispersion j_ of the spray dried powder in the aqueous media.
COATING OF GRANULATION:
500 g of drug granulation are placed in the coating vessel of a Uni-Glatt coater. The above-described coating Q dispersion is sprayed continuously until the desired amount of lipid coat is applied.
EXAMPLE 3
Spray Dried Lipid Emulsion 200 g 5 Talc 40 g
Citroflex-4 40 g
Distilled Water q.s. 700 g
The spray dried lipid emulsion, talc and _30 citroflex-4 are dispersed in distilled water with the help of a suitable lab mixer. The resulting dispersion is passed through a homogenizer to ensure completeness of dispersion. Drug-beads are coated in a fluid bed coating unit as described in Example 1.
35

Claims

WHAT IS CLAIMED IS:
1.. A process for spray-coating medicaments or foods which comprises spraying onto the surface of the substrate medicament or food an aqueous dispersion of a powder, said powder having been formed by spray drying an emulsion comprising a wax and/or lipid, an emulsifying agent and water.
2. The process according to Claim 1 wherein the wax/lipid is partially hydrogenated cottonseed oil.
3. The process according to Claim 1 wherein the wax is carnuba wax.
4. The process according to Claim 1 wherein the wax is castor wax/cutina HR.
5. The process according to Claim 1 wherein the wax is Hoechst wax E.
6. The process according to Claim 1 wherein the wax is paraffin wax.
7. The process according to Claim 1 wherein the wax is ceresin wax.
8. The process according to Claim 1 wherein the wax is bees wax.
9. The process according to Claim 1 wherein the wax is a mixture of carnuba wax and bees wax.
10. The process according to Claim 1 wherein the wax is mixture of Hoechst wax E, bees wax and paraffin wax.
11. The process according to Claim 1 wherein the lipid is glyceryl monostearate. '
12. The process according to Claim 1 wherein the wax/lipid is a mixture of castor wax and glyceryl monostearate.
13. A coating powder produced by spray-drying an emulsion comprising a wax and/or lipid, an emulsifying agent and water.
14. A coating powder according to Claim 13 wherein the wax/lipid is partially hydrogenated cottonseed oil.
15. A coating powder according to Claim 13 wherein the wax is carnuba wax.
16. A coating powder according to Claim 13 wherein the wax is castor wax/cutina HR.
17. A coating powder according to Claim 13 wherein the wax is Hoechst wax E.
18. A coating powder according to Claim 13 wherein the wax is paraffin wax.
19. coating powder according to Claim
13 wherein the wax is ceresin wax.
20. A coating powder according to Claim 13 wherein the wax is bees wax.
21. A coating powder according to Claim 13 wherein the wax is a mixture of carnuba wax and bees wax.
22. A coating powder according to Claim 13 wherein the wax is a mixture of Hoechst wax E. bees wax and paraffin wax.
23. A coating powder according to Claim
13 wherein the lipid is glyceryl monostearate.
24. A coating powder according to Claim
13 wherein the wax/lipid is a mixture of castor wax and glyceryl monostearate.
25. The coated medicament or food produced by the process of Claim 1.
PCT/US1987/000034 1986-01-13 1987-01-09 Aqueous dispersions of waxes and lipids for pharmaceutical coating WO1987004070A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81845586A 1986-01-13 1986-01-13
US818,455 1986-01-13

Publications (1)

Publication Number Publication Date
WO1987004070A1 true WO1987004070A1 (en) 1987-07-16

Family

ID=25225582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1987/000034 WO1987004070A1 (en) 1986-01-13 1987-01-09 Aqueous dispersions of waxes and lipids for pharmaceutical coating

Country Status (2)

Country Link
EP (1) EP0321457A1 (en)
WO (1) WO1987004070A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0301856A2 (en) * 1987-07-28 1989-02-01 Biomeasure, Inc. Delivery system
WO1992001446A1 (en) * 1990-07-20 1992-02-06 Aps Research Limited Sustained-release formulations
EP0559897A1 (en) * 1990-11-30 1993-09-15 Yamanouchi Pharmaceutical Co. Ltd. Quick release coated preparation
FR2779651A1 (en) * 1998-06-16 1999-12-17 Gattefosse Ets Sa PROCESS FOR THE MANUFACTURE OF SUSTAINED RELEASE TABLETS OF ACTIVE INGREDIENT (S) HAVING ZERO-SIZE DISSOLUTION KINETICS
WO2004083310A1 (en) * 2003-03-17 2004-09-30 Hrd Corp. Aqueous wax emulsions and their coating aplications
WO2006032958A2 (en) * 2004-09-24 2006-03-30 Ascor Chimici S.R.L. Composition in micro-pellets with controlled release physiologically active substance, procedure for their preparation and use in the zootechenical sector
WO2006048895A1 (en) * 2004-11-08 2006-05-11 Rubicon Research Pvt. Ltd. Aqueous pharmaceutical coating
WO2008061003A1 (en) * 2006-11-09 2008-05-22 Hrd Corp. Novel wax emulsion coating applications
FR3017775A1 (en) * 2014-02-21 2015-08-28 Denis Et Fils Sas PULVERULENT GRAFT WAX.
WO2023150072A1 (en) 2022-02-01 2023-08-10 Sinclair David A Compositions and methods for the preservation of plant matter

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438797A (en) * 1965-10-21 1969-04-15 Jerry Allen Biddle Sr Method of preparing pharmaceutical tablets
US3935326A (en) * 1967-06-28 1976-01-27 Boehringer Mannheim G.M.B.H. Process for coating tablets with aqueous resin dispersions
US4508703A (en) * 1982-02-17 1985-04-02 Parfums Christian Dior Production of pulverulent mixtures of lipidic and hydrophobic constituents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5362821A (en) * 1976-11-11 1978-06-05 Takeda Chem Ind Ltd Preparation of slow-release drug
GB1594102A (en) * 1977-09-26 1981-07-30 Sankyo Co Ingestible coating compositions
JPS54143518A (en) * 1978-04-26 1979-11-08 Shin Etsu Chem Co Ltd Method for producing coating composition for solid preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438797A (en) * 1965-10-21 1969-04-15 Jerry Allen Biddle Sr Method of preparing pharmaceutical tablets
US3935326A (en) * 1967-06-28 1976-01-27 Boehringer Mannheim G.M.B.H. Process for coating tablets with aqueous resin dispersions
US4508703A (en) * 1982-02-17 1985-04-02 Parfums Christian Dior Production of pulverulent mixtures of lipidic and hydrophobic constituents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0321457A4 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0301856A2 (en) * 1987-07-28 1989-02-01 Biomeasure, Inc. Delivery system
EP0301856A3 (en) * 1987-07-28 1990-07-25 Biomeasure Inc. Delivery system
WO1992001446A1 (en) * 1990-07-20 1992-02-06 Aps Research Limited Sustained-release formulations
EP0559897A1 (en) * 1990-11-30 1993-09-15 Yamanouchi Pharmaceutical Co. Ltd. Quick release coated preparation
EP0559897A4 (en) * 1990-11-30 1993-10-20 Yamanouchi Pharmaceutical Co. Ltd. Quick release coated preparation
FR2779651A1 (en) * 1998-06-16 1999-12-17 Gattefosse Ets Sa PROCESS FOR THE MANUFACTURE OF SUSTAINED RELEASE TABLETS OF ACTIVE INGREDIENT (S) HAVING ZERO-SIZE DISSOLUTION KINETICS
WO1999065471A1 (en) * 1998-06-16 1999-12-23 Gattefosse S.A. Method for making tablets with active principle sustained-release
US6379700B2 (en) 1998-06-16 2002-04-30 Gattefosse S.A. Process for manufacturing tablets for the sustained release of active principle(s)
WO2004083310A1 (en) * 2003-03-17 2004-09-30 Hrd Corp. Aqueous wax emulsions and their coating aplications
US7267743B2 (en) 2003-03-17 2007-09-11 Marcus Oil And Chemical Wax emulsion coating applications
US7776928B2 (en) 2003-03-17 2010-08-17 Hrd Corp. Wax emulsion coating applications
JP4855247B2 (en) * 2003-03-17 2012-01-18 エイチアールディー コーポレイション Water-wax emulsion and its coating application
WO2006032958A2 (en) * 2004-09-24 2006-03-30 Ascor Chimici S.R.L. Composition in micro-pellets with controlled release physiologically active substance, procedure for their preparation and use in the zootechenical sector
WO2006032958A3 (en) * 2004-09-24 2006-08-24 Ascor Chimici Srl Composition in micro-pellets with controlled release physiologically active substance, procedure for their preparation and use in the zootechenical sector
WO2006048895A1 (en) * 2004-11-08 2006-05-11 Rubicon Research Pvt. Ltd. Aqueous pharmaceutical coating
WO2008061003A1 (en) * 2006-11-09 2008-05-22 Hrd Corp. Novel wax emulsion coating applications
FR3017775A1 (en) * 2014-02-21 2015-08-28 Denis Et Fils Sas PULVERULENT GRAFT WAX.
WO2023150072A1 (en) 2022-02-01 2023-08-10 Sinclair David A Compositions and methods for the preservation of plant matter

Also Published As

Publication number Publication date
EP0321457A1 (en) 1989-06-28
EP0321457A4 (en) 1988-11-24

Similar Documents

Publication Publication Date Title
US5023108A (en) Aqueous dispersions of waxes and lipids for pharmaceutical coating
Jannin et al. Hot-melt coating with lipid excipients
Murtaza Ethylcellulose microparticles: A review
EP0129365B1 (en) Enteric coating for pharmaceutical dosage forms
US7179407B2 (en) Zero order release and temperature-controlled microcapsules and process for the preparation thereof
US3737337A (en) Process for the production of microgranulates
US6238704B1 (en) Sustained-release preparation utilizing thermal change and process for the production thereof
US7897179B2 (en) Pharmaceutical composition containing water soluble drug
US5270055A (en) Solid pharmaceutical sustained-release form
WO2001056545A2 (en) Sustained-release microencapsulated delivery system
IE911276A1 (en) Granulated preparations and method of producing the same
WO1987004070A1 (en) Aqueous dispersions of waxes and lipids for pharmaceutical coating
AU2006331009A1 (en) Masking the taste of powders
KR20080074083A (en) Solid formulation for medicine comprising sparingly soluble drug and process for preparing the same
KR100420269B1 (en) Solvent-free solid preparations and subsequent treatment
EA000467B1 (en) Granular preparation and process for producing the same
Lehmann Fluid-bed spray coating
US3379554A (en) Spray coating of pharmaceutical cores with a carboxylvinyl polymer and polyethylene glycol
EP0745383B1 (en) Method for producing an enteric preparation coated with a enteric coating agent powder using a liquid plasticizer
JPH0138091B2 (en)
JP2506048B2 (en) Capsule-containing bath agent composition
JPH08333238A (en) Enteric coated preparation coated by solventless enteric coating agent using liquid wax
JP3628401B2 (en) Enteric preparation with solvent-free enteric coating
JP3417772B2 (en) Solvent-free coated solid preparation and subsequent treatment method
Almadanti et al. Microencapsulation to Maintain the Activity and Stability of Drug Substances: A Review: Activity, Stability, Coacervation, Microencapsulation, Spray Drying, Solvent Evaporation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): DK JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1987900713

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1987900713

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1987900713

Country of ref document: EP